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Background: Prediction of the slope of cognitive deterioration in Parkinson‘s disease (PD) is 
important for subgroup-specific treatment.  Besides Lewy body pathology, Amyloid-β (Aβ) and 
Tau pathology have been discussed as potential modifying agents and are reflected by altered 
cerebrospinal fluid (CSF) levels of Aβ1-42, total-Tau (t-Tau) and phosphorylated-Tau (p-Tau).  
Objective: To evaluate the evolution of cognitive impairment in relation to CSF profiles in PD. 
Methods: Prospective, longitudinal, observational study up to 10 years with follow-up every 
two years. We assessed CSF profiles in 415 sporadic PD patients (median age 66; 63% male) 
and 142 healthy controls (median age 62; 43% male).  
Results: PD patients with low CSF Aβ1-42 levels at baseline were more often cognitively 
impaired than patients with intermediate and high Aβ1-42 levels. Sixty-seven percent of the 
patients with low Aβ1-42 levels at baseline and normal cognition developed cognitive 
impairment during follow-up, compared to 41% and 37% of patients having intermediate and 
high CSF Aβ1-42 levels. Kaplan Maier Survival Curves and Cox Regression revealed that 
patients with low CSF Aβ1-42 levels at baseline developed cognitive impairment more 
frequently and earlier during follow-up. 
Conclusion: Aβ1-42 CSF profiles in PD patients might be useful for predicting phenotypic 





Parkinson’s disease (PD) is a complex disorder with multifactorial etiology, heterogeneity in 
phenotypes and variability in progression of motor and non-motor symptoms. This calls for 
prediction and progression biomarkers in order to monitor the course of neurodegeneration, and 
to establish endpoints for therapeutic strategies aiming to modify disease progression. 
A possible explanation for the clinical variability in PD patients might be an inter-individual 
heterogeneity in the underlying pathogenesis and pathologic processes 1, 2. In addition to the 
typical Lewy body pathology, a considerable proportion of patients have β-amyloid (Aβ) and 
Tau pathology at autopsy, predominantly presenting a clinical phenotype with dementia in their 
disease course 3, 4. Several studies have reported altered CSF levels of Aβ1-42, total-Tau (t-Tau) 
and phosphorylated-Tau (p-Tau) in sporadic PD patients. The most robust results indicate 
decreased levels of Abeta1_42 to be associated with cognitive impairment 
5-10. However, 
longitudinal data of these protein levels in CSF and its evolution over the course of the disease 
are rather limited. Additionally, it is unclear to what degree these protein alterations are 
involved in PD pathogenesis or rather represent concomitant pathology or aging processes and 
whether they are influenced by genetic variation. In the era where disease-modifying treatment 
options are starting to emerge, these gaps need to be filled in order monitor and dissect disease 
progression and treatment effects. 
 
Participants and Methods 
Participants 
All PD patients reported in this study were recruited between 2003 and 2017 and are patients 
of the ward and/or outpatient clinic for PD at the University Hospital Tuebingen. Some of them 
are participants of PD-related clinical prospective longitudinal studies of our Department 11, 12. 
Spouses and relatives of PD patients and volunteers recruited by newspaper advertisements 
were assessed and only those with no indication for a neurodegenerative disease were selected 
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as healthy control individuals (CON). All PD patients were controlled to have no p.G2019S 
LRRK2 mutation or one of the most frequent GBA mutations (p.L444P; p.N370S, p.E326K). 
Moreover, patients were screened for mutations in Parkin and PINK1 if the following criteria 
were fulfilled: age of onset ≤ 40 years or a positive family history compatible with a recessive 
mode of inheritance. In total, CSF data from 415 PD patients and 142 CON participants were 
available for the cross-sectional analysis. Of the 415 participants with PD, 274 completed a 2-
year, 162 a 4-year, 76 a 6-year, 36 an 8-year, and 19 a 10-year follow-up of clinical assessment 
and partially also of lumbar puncture.  
 
Clinical Investigations 
At each time point, all subjects including the healthy controls were examined by a neurologist 
(DB, FB, KB, GM, WM, BR, IW, MZ) blinded to the results of the CSF marker analysis. PD 
patients were assessed in the dopaminergic ON state. Diagnosis of PD was defined according 
to UK Brain Bank Society Criteria 13. We assessed severity of motor symptoms using part III 
of the Unified Parkinson’s disease Rating Scale (UPDRS-III from 2003-2008, MDS-UPDRS 
from 2009 on 14). Disease stage was categorized by the modified Hoehn and Yahr Scale (H&Y) 
15. Cognitive function was tested using the Montreal Cognitive Assessment (MoCA) 16 and/or 
the Mini Mental Status Examination (MMSE) 17. Since the MoCA was only available from 
2009 on, we converted the MMSE scores into MoCA equivalent scores according to the 
algorithm published recently 18. Hence, a valid MoCA score was available for each subject at 
each time point. A MoCA cut off ≤25 was used as the point for maximum combined sensitivity 
and specificity for cognitive impairment 19. 
 
Collection of CSF samples and CSF Marker Analysis 
CSF collection and determination of routine diagnostic parameters were performed according 
to standardized protocols 20. In brief, spinal tap was performed between 9.00am and 1.00pm. 
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Individuals were in a sitting position and the needle was tapped in the L3-4 or L4-5 interspace. 
Samples were directly taken from the bedside and centrifuged within 30 minutes after collection 
and frozen at −80°C within 60 minutes after collection. Only samples of subjects with normal 
routine CSF diagnostics (white blood cell count <4*106/l, IgG index <0.6) were included. CSF 
levels of Aβ1-42, t-Tau and p-Tau (phosphorylated at T181) were measured in Tuebingen using 
commercially available ELISA kits (INNOTEST; Fujirebio Germany GmbH, Hannover, 
Germany). The antibodies bind specifically to the sequences MVGGVV (first antibody: 21F12) 
and DAEFRH (second antibody: 3D6), detecting Aβ right from the first amino acid. The 
measurements were performed by board-certified laboratory technicians who were blinded to 
clinical data. To check for longitudinal stability of the measurements, two internal longitudinal 
quality control samples (QC) were run on each plate (supplemental Table 1). The intra-assay 
coefficients of variation for each CSF parameter were below 15%. Quality data of the 
Tuebingen laboratory within this program can be found in supplemental Table 2. The 
Tuebingen laboratory is part of the Alzheimer’s Association Quality Control Program for CSF 
Biomarkers 21.  
For further subgroup analysis, PD patients were classified based on their individual baseline 
levels of CSF Aβ1-42 according to internal standards and similar to Palmqvist et al.22 into the 
following groups: high: ≥ 600pg/ml, intermediate: 599-300 pg/ml and low: <300 pg/ml.  
 
Genetics 
All samples were genotyped using the Illumina Neurochip array (ref: PMID:28602509). 
Genotypes for the APOE haplotype (rs429358 and rs7412) were extracted from the larger 





Statistical analysis was performed using IBM SPSS 22.0 software for Windows SPSS (Inc, 
Chicago, IL, USA).  
1. Cross-sectional comparisons of demographic, clinical and CSF markers between PD 
and CON at baseline were calculated by ANOVA. Dichotomous data were analyzed using the 
Fisher Exact Test. Differences were considered significant at p < 0.05. 
2. Multiple linear regression analyses were used to evaluate independent effects of 
demographic and clinical data at baseline (independent variables: age, gender, disease duration, 
CSF levels of Aβ1-42, t-Tau and p-Tau) on MoCA scores (dependent variable) in PD patients 
for each time point. Differences were considered significant at p < 0.05.  
3. Kaplan Mayer survival curves and Cox proportional hazard models stratified by the 
Aβ1-42 subgroup (high vs. median vs. low) were used to estimate disease duration free from 
cognitive impairment (MoCA≤25) in PD patients. Time to event was defined as disease 
duration until first clinical diagnosis of cognitive impairment. Risk of development of cognitive 
impairment was calculated with Cox proportional hazards models to estimate hazard ratios 
(HRs) with 95% confidence intervals (95% CIs) and p-values for pairwise comparisons.  
 
Protocol Approvals and Patient Consents 
The study was approved by the Ethics Committee of the Faculty of Medicine at the University 
of Tuebingen (199/2011BO1). All participants gave written informed consent. 
 
Results 
1. Inter-group characteristics 
Baseline characteristics of demographic and clinical data stratified by cohort are shown in Table 
1. PD patients were older, more often male and had lower MoCA scores compared to CON. 
Within the PD group, those with cognitive impairment were older at disease onset and at clinical 
7 
 
visit and had higher (MDS-)UPDRS-III scores and higher H&Y stages compared to PD patients 
with normal cognitive profiles (p<0.001 respectively).  
 
2. Association between demographic data, clinical characteristics and CSF levels with MoCA 
scores in PD patients 
Higher age and longer disease duration were associated with lower MoCA scores at baseline 
(age: p<0.001; disease duration: p<0.001), after two years (age: p<0.001; disease duration 
p<0.001), after four years (age: p<0.001; disease duration: p=0.014) and after six years (age: 
p=0.033; disease duration: p=0.001). Lower CSF Aβ1-42 levels were associated with lower 
MoCA scores at baseline, after two years and after four years (baseline: p=0.004, two years: 
p=0.046, four years: p=0.050). Male gender was associated with lower MoCA scores after eight 
years (p=0.040). No association were found for CSF levels of t-Tau and p-tau with MoCA. For 
details see Table 2. 
 
3. Progression to cognitive impairment in relation to CSF Abeta1_42 levels 
a) Kaplan Mayer survival curves and Cox proportional hazard models stratified by CSF Aβ1-42 
subtype with development of cognitive impairment as outcome 
Participants classified as “low CSF Aβ1-42 subgroup” (<300 pg/ml) had a higher risk of 
developing cognitive impairment (HR (95% CI) = 1.66 (1.27-2.18); p<0.001) and developed 
cognitive impairment earlier in the disease course compared to those classified as intermediate 
and high CSF Aβ1-42 subgroup (5.9 years disease duration vs. 9.8 and 10.5 years disease 
duration; p=0.006) (Figure 1 and 2). 
b. Demographics and development of cognitive impairment based on CSF Aβ1-42 subtype  
PD patients with low Aβ1-42 levels (<300pg/ml) were older at disease onset and older at baseline 
study visit. They had lower MoCA scores and were more often cognitively impaired at baseline 
compared to patients with intermediate and high levels of Aβ1-42. Of those patients classified as 
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“low CSF Aβ1-42 subgroup” and who were not cognitively impaired at baseline, 67% developed 
cognitive impairment during follow-up compared to 41% and 37% of PD patients classified as 
intermediate and high CSF Aβ1-42 subgroup (p=0.038) (Table 3). The observation interval for 
those PD patients not reaching the milestone “cognitive impairment” was 4 ± 1 years (<300 
pg/ml), 8 ± 4 years (599-300 pg/ml) and 9 ± 4 years (≥600 pg/ml).  
c. Demographics and clinical characteristic of PD patients who newly developed cognitive 
impairment compared to those free from cognitive impairment at last clinical follow-up visit. 
During the observation period, 65 PD patients newly developed cognitive impairment (42 at 2-
years, 13 at 4-years, 10 at 6-years). This subgroup was older at disease onset, older at baseline 
study visit, had lower MoCA scores and higher H&Y stages at baseline, compared to those 
patients free from cognitive impairment at last clinical follow-up visit. See Figure 1-part B and 
Table 4. 
 
4. Association of APOE genotype with CSF Aβ1-42 levels in PD patients 
PD patients with at least one APOE ε4 allele had lower CSF levels of Aβ1-42 compared to 
patients with no APOE ε4 allele (Aβ1-42: 577 pg/ml vs. 732 pg/ml; p<0.001). As the number of 
PD patients carrying two APOE ε4 alleles was small (n=7), we did not perform a separate 
statistical analysis. PD patients with at least one APOE ε4 allele did not differ in demographics 
and clinical characteristics compared to those patients with no APOE ε4 allele (Table 5). 
 
Discussion 
The clinical presentation of motor and non-motor symptoms and the prognostic outcome of PD 
are highly variable. There is increasing evidence that proteins such as Aβ1-42 and Tau indicate 
the presence of disease modifiers and thereby explain part of the variety of the clinical 
phenotype 3, 4, 23. 
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By examining CSF Aβ1-42, t-Tau and p-Tau levels cross-sectionally in sporadic PD patients, we 
could show that: (I) Higher age, longer disease duration and lower levels of Aβ1-42 were 
associated with worse cognitive performance assessed by the MoCA; (II) PD patients with low 
Aβ1-42 levels were more frequently cognitively impaired at baseline and more often developed 
cognitive decline during the observation period; (III) presence of at least one APOE ε4 allele is 
associated with lower CSF levels of Aβ1-42 in PD patients. 
By assessing CSF levels of Aβ1-42, t-Tau and p-Tau longitudinally, we could confirm main 
findings from the cross-sectional analyses: (I) Higher age, longer disease duration and lower 
levels of Aβ1-42 were associated with worse cognitive performance assessed by the MoCA at 
two, four and six years of follow-up; (II) Lower levels of Aβ1-42 were associated with a higher 
proportion of PD patients developing cognitive impairment earlier during the disease course.  
Evidence that proteins such as A act as disease modifiers comes not only from genetic but also 
from histopathological studies: a considerable proportion of sporadic PD patients who 
displayed concomitant AD pathology at autopsy, in addition to the expected Lewy body 
pathology, presented with dementia before death 2, 3, 24. The association of reduced Aβ1-42 levels 
with PD-associated dementia is in line with findings from several cross-sectional studies 8, 25, 26 
and a limited number of longitudinal investigations 27-29. Therefore, CSF profiles of Aβ1-42 
might be useful for monitoring phenotypic variability with focus on cognitive impairment in a 
subgroup of PD patients. 
However, at this point, we know little in terms of the timely and quantitative evolution of CSF 
A profiles in relation to the development of cognitive decline in PD. When does a decrease of 
CSF Aβ1-42 in relation to the onset of PD-associated cognitive decline occur and what might be 
the best diagnostic cut-off for clinical routine? Do we need age-dependent and disease-specific 
cut-offs? Studies in inherited forms of Alzheimer’s disease report a sequential occurrence of 
different biofluids, imaging and clinical markers. In this context, the reduction of CSF Aβ1-42 
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levels seems the earliest marker and occurs about 25 years before the expected clinical symptom 
onset 30.  
It would also be interesting to know to what degree genetic variation promotes pathologic 
aggregation of different protein species possibly reflected by CSF profiles. There is evidence 
that the APOE ε4 allele promotes A pathology 31 and consecutively is associated with reduced 
CSF levels of Aβ1-42 and an increased risk of developing PD-associated cognitive decline as 
shown in the present study as well as reported by others and even in the PPMI study in early 
stage PD patients 32, 33. 
 
A strength of our study is the measurement of CSF Aβ1-42 levels in a large monocentric 
longitudinal cohort according to standardized operating procedures (SOP) of clinical 
assessments and sample preparation and biomarker analyses27. It has been shown that large 
multicenter cohorts might face the problem that site-specific effects can pose an important 
confounder despite given SOPs for clinical and biomaterial work-up.  
Limitations of the present study are as follows: (I) With increasing follow-up time, especially 
patients with cognitive decline dropped out of the study limiting the validity of CSF levels 
especially at later stages of the long follow-up period. (II) Although converting scales for 
MMSE into MoCA are available, both tests do not exactly capture the same cognitive domains 
to the same amount (e.g. MoCA captures better executive dysfunction whereas MMSE focuses 
on memory and orientation) and both have different ceiling effects. More sophisticated clinical 
assessments are in need in order to evaluate distinct cognitive domains in relation to CSF 
profiles. 
We conclude that in sporadic PD patients, low levels of Aβ1-42 are associated with a higher risk 
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Table 1: Clinical characteristics of healthy controls and PD patients at baseline 
 
Abbreviations: H&Y, Hoehn and Yahr; MoCA, Montreal Cognitive Assessment; UPDRS-III, Unified 
Parkinson’s Disease Rating Scale part 3. Data are shown as mean and standard deviation or N (%). 













































Male gender, n (%) 67 (47) 260 (63) 0.001 140 (62) 116 (64) 0.758 
Age [years] 62 ± 12 66 ± 10 <0.001 63 ± 9 70 ± 8 <0.001 
Age at onset [years] - 60 ± 10  58 ± 9 63 ± 10 <0.001 
Disease duration [years] - 6 ± 5  6 ± 4 8 ± 5 <0.001 
MoCA (0-30) 28 ± 2 25 ± 4 0.034 28 ± 1 21 ± 4 <0.001 
UPDRS-III (0-163) - 26 ± 12  23 ± 10 29 ± 13 <0.001 
H&Y (0-5) - 2 ± 1  2 ± 1 2 ± 1 <0.001 
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Table 2: CSF levels of Abeta1_42, t-tau, p-tau and demographics as predictors of MoCA 
scores in PD patients  
 

































 BL 2 years 4 years 6 years 8 years 
Independent variables n=377 n=215 n=131 n=63 n=24 
Gender 0.008 0.002 -0.095 -0.129 -0.401* 
Age [years] -0.382*** -0.313*** -0.436*** -0.247* -0.229 
Disease duration [years] -0.197*** -0.247*** -0.193* -0.399** -0.680** 
CSF Abeta1-42 [pg/ml] 0.133** 0.110* 0.149* 0.091 0.293 
CSF total-Tau [pg/ml] -0.011 -0.001 -0.011 0.173 0.241 
CSF phospho-Tau [pg/ml] -0.033 -0.081 -0.017 0.162 0.256 
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Table 3: Clinical characteristics and development of cognitive impairment in PD 
patients stratified by CSF Abeta1-42 subgroup at baseline 
Abbreviations: CSF, Cerebrospinal fluid; H&Y, Hoehn and Yahr; MoCA, Montreal Cognitive 
Assessment; UPDRS-III, Unified Parkinson’s Disease Rating Scale part 3. Data are shown as mean and 
standard deviation or N (%). 
























 Abeta1-42  






<300 pg/ml  
n=20 
p-value 
Male gender, n (%) 157 (64) 92 (62) 11 (55) 0.740 
Age [years] 66 ± 10 67 ± 9 72 ± 6*# 0.012 
Age at onset [years] 59 ± 10 60 ± 10 68 ± 6*# <0.001 
Disease duration [years] 7 ± 5 7 ± 5 5 ± 4 0.277 
MoCA (0-30) 25 ± 4 24 ± 5 21 ± 5*# <0.001 
UPDRS-III (0-163) 26 ± 10 26 ± 14 26 ± 15 0.751 
H&Y (0-5) 2 ± 1 2 ± 1 2 ± 1 0.211 
Cognitively impaired at 
baseline, n (%) 




during  observation 
period , n (%) 
 





Table 4: Baseline clinical characteristics and CSF Abeta1_42 levels in PD patients who 
newly developed cognitive impairment during follow up compared to those free from 
cognitive impairment 
 
Abbreviations: CSF, Cerebrospinal fluid; H&Y, Hoehn and Yahr; MoCA, Montreal Cognitive 
Assessment; UPDRS-III, Unified Parkinson’s Disease Rating Scale part 3. Data are shown as mean and 





















 No cognitive 










Male gender, n (%) 61 (62) 42 (65) 0.868 
Age [years] 63 ± 9 67 ± 9 0.006 
Age at onset [years] 58 ± 9 61 ± 9 0.024 
Disease duration [years] 5 ± 4 6 ± 4 0.323 
MoCA (0-30) 28 ± 1 27 ± 1 0.017 
UPDRS-III (0-163) 23 ± 9 24 ± 11 0.339 
H&Y (0-5) 2 ± 1 2 ± 1 0.030 
CSF Abeta 1-42 [pg/ml] 720 ± 253 702 ± 259 0.816* 
19 
 
Table 5: Baseline demographics, clinical characteristics and CSF profiles of PD patients 
stratified by APOE genotype 













Male gender, n (%) 52 (21) 4 (2) 56 (22) 195 (78) 0.187 
Age [years] 65 ± 10 65 ± 6 65 ± 10 66 ± 10 0.136 
Age at onset [years] 58 ± 9 59 ± 7 58 ± 9 60 ± 10 0.124 
Disease duration [years] 7 ± 5 7 ± 5 7 ± 5 6 ± 5 0.852 
MoCA (0-30) 25 ± 4 25 ± 4 25 ± 4 25 ± 4 0.600 
UPDRS-III (0-163) 25 ± 12 24 ± 15 25 ± 12 26 ± 11 0.495 
H&Y (0-5) 2 ± 1 2 ± 1 2 ± 1 2 ± 1 0.835 
CSF Abeta 1-42 [pg/ml] 583 ± 223 500 ± 191 577 ± 222 732 ± 277 <0.001 
CSF total-Tau [pg/ml] 244 ± 147 239 ± 123 243 ± 145 247 ± 143 0.841 
CSF phosphorylated-Tau 
[pg/ml] 
42 ± 20 42 ± 16 42 ± 19 43 ± 18 0.580 
Cognitively impaired at baseline, n 
(%) 
31 (35) 4 (57) 35 (37) 137 (46) 0.100 
Interval to cognitive impairment 
(total) [years] 
8 ± 5 7 ± 3 8 ± 5 8 ± 5 0.353 
 
Development of cognitive 
impairment during observation 
period, n (%)a 
19 (43) 1 (50) 20 (44) 43 (38) 0.592 
Interval to cognitive impairment 
(conversion during observation 
period) [years]a 
8 ± 3 7 ± 0 8 ± 3 8 ± 4 0.601 
 
Abbreviations: APOE, Apolipoprotein; CSF, Cerebrospinal fluid; H&Y, Hoehn and Yahr; 
MoCA, Montreal Cognitive Assessment; UPDRS-III, Unified Parkinson’s Disease Rating 
Scale part 3. 
N=16 (4%) with missing APOE status; The p-value refers to group comparison of no APOE 
ε4 allele versus at least one APOE ε4 allele. a n=65 developed cognitive impairment during 







Figure 1: Evolution of CSF Abeta1-42 levels in healthy controls and PD patients stratified 
by cognitive status over 8 years 
 
 
Lines represent median values over time. A) All available CSF time points of PD patients and healthy 
controls B) CSF time points of all healthy controls and PD patients of whom CSF was available 
at baseline, six and eight year follow-up.  
The black line represents PD patients who developed cognitive impairment during observation 
period with CSF Abeta1_42 levels at last clinical visit free from cognitive impairment and at 


















Figure 2: Kaplan-Meier survival curves show the association between baseline CSF 




Kaplan-Meier curves show disease duration free from cognitive impairment in PD patients classified by 
their baseline CSF Abeta1-42 levels. The graphs demonstrate data with respect to disease duration 
(defined as the time from disease diagnosis until first clinical diagnosis of cognitive impairment). Hazard 
ratios (HR) with 95% confidence intervals (95% CI) and p-values from univariate Cox proportional 
hazard models with high Abeta1-42 subgroup adopted as reference group. 
 
